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ABSTRACT
Cyclin-dependent kinase 4 (CDK4) is a positive regulator of cell cycle progression, however, there is
growing evidence demonstrating that its function exceeds the control of cell division. Here we show that
CDK4 is an important regulator of cellular substrate utilization through direct inhibition of the metabolic
regulator AMPK (AMP-activated protein kinase). KEYWORDS
Cell Cycle; Metabolism; CDK4;
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Metabolic adaptation has been recently found in the spotlight for
research due to its importance for numerous physiological pro-
cesses, like insulin responsiveness by liver and white adipose tis-
sue, cold responsiveness by brown adipose tissue, exercise
performance bymuscle, and T cell response to an infection.Meta-
bolic remodeling is also a hallmark of cancer cells,1 and character-
izes pathological states, like insulin resistance and aging.2
In recent years, we and others have discovered key roles for
cell cycle regulators in the control of metabolic processes in
physiological and pathological conditions. Amongst these, the
cyclin dependent kinase 4 (CDK4) is now recognized as not
only a coordinator between cellular metabolism and cell cycle
progression,3 but also a key metabolic regulator in differenti-
ated, non-proliferating cells.4 Indeed, CDK4 has been shown to
promote adipose tissue differentiation by phosphorylating and
activating Peroxisome proliferator-activated receptor gamma
(PPAR-g),5 to maintain a positive feedback loop in the insulin
signaling pathway by phosphorylating Insulin Receptor Sub-
strate 2 (IRS2)6 and to suppress hepatic glucose production by
phosphorylating and activating general control non-repressed
protein 5 (GCN5).7 CDK4 has also been shown to participate
in the control of metabolism via the canonical CDK4-pRB-
E2F1 pathway, involving the retinoblastoma protein (RB1, best
known as pRB) and the E2F1 transcription factor.3 All these
evidence suggest that CDK4 promotes anabolic processes.
Interestingly, by characterizing substrate utilization in mouse
embryonic ﬁbroblasts (MEFs) lacking CDK4 (Cdk4¡/¡) or
expressing a hyperactive version of the protein (Cdk4R24C/R24C),
we determined that CDK4 promotes anaerobic glycolysis, while
preventing fatty acid oxidation (FAO). This led to our discov-
ery of a novel, unexpected function for CDK4, in phosphorylat-
ing and repressing the a2 subunit of the major regulator of
oxidative metabolism AMPK (AMP-activated protein kinase).8
The use of chemical inhibitors of CDK4 (LY2835219) drives
increased FAO in MEFs, as well as in muscle cells, in an AMPK
dependent manner. This ﬁnding was further supported by the
fact that AMPKa2 mutants that cannot be phosphorylated by
CDK4 have increased capacity to promote FAO, when com-
pared to their wild type AMPKa2 counterpart.9
Given that muscle highly express the a2 subunit of AMPK
and responds to exercise by down regulating CDK activity
and concomitantly increasing AMPK activity and FAO,10 we
set out to investigate a potential role for the FAO regulation
by CDK4 in muscle function. Interestingly, mice lacking
CDK4 in all tissues except in pancreatic beta cells, show
increased exercise capacity and decreased respiratory exchange
ratio (RER), suggesting higher levels of oxidative metabolism.
The treatment of wild type mice with LY2835219 led to a sim-
ilar increase in exercise capacity and to a similar decrease of
RER. This phenotype was dependent on the activity of AMPK
in muscle.9
Overall, we believe that CDK4 can rapidly modulate metab-
olism in proliferating and differentiated cells, as well as at a
whole body level. Metabolic pathways, including the AMPK
and insulin/insulin-like growth factor 1 (IGF-1) signaling path-
ways are increasingly becoming druggable targets for anti-
tumor therapies. Therefore, the ﬁnding that CDK4 promotes
proliferation, maintains the insulin signaling pathway, and
therefore lipid synthesis, while repressing FAO, is of great
interest for translational research given that three different
CDK4/6 inhibitors PD0332991 (palbociclib), LY-2835219 (abe-
maciclib) and LEE011 (ribociclib) are currently approved for
the treatment of breast cancer or are currently in advanced
stages of clinical trials for certain cancers.
In a broader sense, our study underscores the necessity for
cells and whole organisms to establish integrated responses
that will ensure a proper metabolic response to external cues.
For instance, in the case of cell cycle, mitogen response needs
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to be coupled to a concerted program to fulﬁll both the neces-
sity for important energy stores, as well as the requirement for
biosynthetic intermediates for nucleic acids, proteins and lipids.
This can be orchestrated in a timely manner by using cell cycle
regulators to integrate extracellular signals (i.e. mitogens) and
regulate signaling pathways in a coordinated manner. At
the level of the whole organism, such metabolic master reg-
ulators could also ensure a proper metabolic adaptation
from the tissues to external stimuli, such as exercise, diet
and nutrition.
Our recent study places CDK4 as one of such metabolic reg-
ulators, which has the ability to promote anabolism, while
directly repressing catabolism by inhibiting AMPK (Fig. 1).
Our ﬁndings indicate that therapeutic strategies targeting
CDK4 may have unforeseen beneﬁcial effects, due to the meta-
bolic functions of this cell cycle regulator in pathologies ranging
from metabolic disorders to cancer.
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Figure 1. CDK4 functions as a cellular sensor of energy status. In anabolic conditions, cyclin-dependent kinase 4 (CDK4) is bound to D-type cyclins (CycD) and therefore,
active. In these conditions, it promotes glycolysis as well as biosynthetic pathways, while repressing fatty acid oxidation (FAO) via the inhibition of the a2 subunit of the
AMP-activated protein kinase (AMPKa2). On the other hand, when energy levels are low, CDK4 is inactive. Hence, ATP producing processes, like FAO, are triggered in
order to restore cellular energy homeostasis and respond to energy stress.
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